Press Release

NATCO Pharma Ltd

NATCO House
Road No.2, Banjara Hills
Hyderabad-500 034, India

Hyderabad, India, August 12th, 2025: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today announced results for first quarter of financial year 2026.

NATCO records ₹1,390.6 Crore consolidated revenue and ₹480.3 Crore of profit after tax for Q1FY26

NATCO recorded consolidated total revenue of INR 1,390.6 Crore for the quarter ended on 30th June, 2025 as against INR 1,410.7 crore as of 30th June, 2024. EBITDA for the quarter was at INR 632.7 Crore with margins at 45.5%. The net profit for the period, on a consolidated basis was INR 480.3 Crore.

During the quarter, the business faced pricing pressure in the US product portfolio and incurred increased R&D expenses on account of high value projects.

The Board of Directors have declared an interim dividend of INR 2 per equity share of INR 2 each during Q1FY26.

Segmental Revenue Split (INR Cr)

Segment	Q1FY26	Q4FY25	Q1FY25
Active Pharmaceutical Ingredients (API)	52.6	46.4	39.2
Domestic Formulations	107	99.4	102.2
Formulations export (Incl. profit share and subs)	1,126.5	1,052.5	1,210.1
Crop Health Sciences (CHS)	34.7	15.0	15.6
Other operating and non-operating income	69.8	74.0	43.6
Total	**1,390.6**	**1,287.3**	**1,410.7**

NATCO Pharma Ltd

NATCO House
Road No.2, Banjara Hills
Hyderabad-500 034, India

About NATCO Pharma Limited

NATCO Pharma Limited (www.natcopharma.com), (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company's different manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at www.natcopharma.com or click on LinkedIn or X (formerly Twitter)

For further information please contact:

Rajeev Menon, Investor Relations

r.menon@natcopharma.co.in/investors@natcopharma.co.in

Rajesh Chebiyam, EVP - CHS

rajesh.chebiyam@natcopharma.co.in

Earnings Call Details:

- *Date: 13th August 2025, Wednesday*
- *Time: 11 AM IST*
- ***Dial-in-Numbers:***
  - *India: (+91 22) 62801222 / 71158123*
  - *US: 18667462133*
  - *UK: 08081011573*
  - *Singapore: 8001012045*
- *Pre-register using the link: https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=6402328&linkSecurityString=301158e510*